Home » Dual Effort to Improve FDA Drug Reviews Moves to House Floor
Dual Effort to Improve FDA Drug Reviews Moves to House Floor
May 12, 2006
Efforts to strengthen the FDA’s drug reviews passed a major legislative hurdle last week as lawmakers in the House Appropriations Committee agreed to amendments banning conflict-of-interest waivers for agency advisory boards and giving the agency the
authority to mandate postmarket studies.